CYTOSORBENTS CORPORATION - COMMON STOCK

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

28 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

13 12 2023 08:15:00 提供 Nasdaq GlobeNewswire

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

09 11 2023 15:15:00 提供 Nasdaq GlobeNewswire

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

27 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents to Present at the 8th Annual Dawson James Conference

05 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

27 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

19 9 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation

11 9 2023 10:32:17 提供 Nasdaq GlobeNewswire

CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico

01 9 2023 15:43:18 提供 Nasdaq GlobeNewswire

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

31 8 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Reports Second Quarter 2023 Financial and Operational Results

01 8 2023 15:15:01 提供 Nasdaq GlobeNewswire

CytoSorbents to Report Second Quarter 2023 Operating and Financial Results

26 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer

19 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

11 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

07 7 2023 06:07:00 提供 Nasdaq GlobeNewswire

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

15 6 2023 06:00:01 提供 Nasdaq GlobeNewswire

CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference

05 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents Reports First Quarter 2023 Results

02 5 2023 15:15:00 提供 Nasdaq GlobeNewswire

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

26 4 2023 06:00:00 提供 Nasdaq GlobeNewswire

CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled

20 4 2023 06:00:01 提供 Nasdaq GlobeNewswire